NextCure Long Term Debt vs Current Deferred Revenue Analysis

NXTC Stock

USD 1.54 0.04 2.53%

NextCure financial indicator trend analysis is infinitely more than just investigating NextCure recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NextCure is a good investment. Please check the relationship between NextCure Long Term Debt and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

Long Term Debt vs Current Deferred Revenue

Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NextCure Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between NextCure's Long Term Debt and Current Deferred Revenue is 0.45. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of NextCure, assuming nothing else is changed. The correlation between historical values of NextCure's Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of NextCure are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Long Term Debt i.e., NextCure's Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that NextCure has held for over one year. Long-term debt appears on NextCure balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on NextCure balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from NextCure's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NextCure current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 1.25, whereas Selling General Administrative is forecasted to decline to about 14.9 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	7.2M	4.1M	3.9M	3.7M
Total Operating Expenses	70.8M	75.9M	64.0M	56.1M

Reconciled Depreciation Total Operating Expenses

NextCure fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.72	0.94	0.93	0.95	0.45	0.93	0.77	0.6	-0.27	-0.54	0.7	0.31	0.83	0.64	0.77	0.86	1.0	0.82	0.71	0.86	-0.25	0.83	0.26	0.75	0.63
Short Long Term Debt Total	0.72		0.9	0.59	0.81	0.02	0.85	0.83	0.17	0.13	-0.86	0.65	-0.07	0.86	0.85	0.53	0.84	0.7	0.95	0.91	0.84	-0.56	0.95	0.64	0.93	0.88
Other Current Liab	0.94	0.9		0.82	0.97	0.2	0.98	0.87	0.38	-0.02	-0.74	0.74	0.08	0.92	0.79	0.71	0.92	0.93	0.95	0.88	0.92	-0.49	0.96	0.47	0.88	0.81
Total Current Liabilities	0.93	0.59	0.82		0.8	0.66	0.79	0.67	0.79	-0.47	-0.48	0.69	0.52	0.78	0.64	0.78	0.78	0.93	0.7	0.55	0.78	0.0	0.71	0.32	0.55	0.46
Total Stockholder Equity	0.95	0.81	0.97	0.8		0.17	0.99	0.79	0.38	0.05	-0.59	0.66	0.0	0.85	0.66	0.77	0.93	0.94	0.89	0.8	0.93	-0.55	0.9	0.3	0.82	0.72
Other Liab	0.45	0.02	0.2	0.66	0.17		0.15	0.02	0.95	-0.86	0.1	0.15	0.87	0.11	0.07	0.37	0.2	0.46	0.05	-0.12	0.2	0.68	0.07	-0.17	0.05	-0.18
Net Tangible Assets	0.93	0.85	0.98	0.79	0.99	0.15		0.8	0.36	0.06	-0.66	0.66	-0.01	0.87	0.73	0.73	0.95	0.92	0.94	0.84	0.95	-0.56	0.95	0.38	0.83	0.77
Property Plant And Equipment Net	0.77	0.83	0.87	0.67	0.79	0.02	0.8		0.11	-0.08	-0.82	0.95	0.14	0.97	0.87	0.6	0.67	0.75	0.87	0.94	0.67	-0.41	0.88	0.66	0.76	0.92
Current Deferred Revenue	0.6	0.17	0.38	0.79	0.38	0.95	0.36	0.11		-0.69	0.0	0.2	0.71	0.26	0.19	0.55	0.45	0.62	0.23	0.0	0.45	0.44	0.24	-0.09	0.17	-0.09
Net Debt	-0.27	0.13	-0.02	-0.47	0.05	-0.86	0.06	-0.08	-0.69		-0.1	-0.29	-1.0	-0.07	-0.07	-0.17	0.12	-0.28	0.07	0.09	0.12	-0.85	0.07	0.14	0.08	0.09
Retained Earnings	-0.54	-0.86	-0.74	-0.48	-0.59	0.1	-0.66	-0.82	0.0	-0.1		-0.69	0.04	-0.82	-0.9	-0.23	-0.62	-0.52	-0.85	-0.88	-0.62	0.44	-0.83	-0.9	-0.73	-0.87
Accounts Payable	0.7	0.65	0.74	0.69	0.66	0.15	0.66	0.95	0.2	-0.29	-0.69		0.35	0.92	0.83	0.64	0.52	0.69	0.73	0.8	0.52	-0.18	0.74	0.61	0.54	0.79
Cash	0.31	-0.07	0.08	0.52	0.0	0.87	-0.01	0.14	0.71	-1.0	0.04	0.35		0.14	0.14	0.21	-0.07	0.32	-0.01	-0.04	-0.07	0.82	-0.01	-0.07	-0.05	-0.04
Non Current Assets Total	0.83	0.86	0.92	0.78	0.85	0.11	0.87	0.97	0.26	-0.07	-0.82	0.92	0.14		0.92	0.71	0.8	0.82	0.93	0.91	0.8	-0.43	0.93	0.68	0.73	0.87
Non Currrent Assets Other	0.64	0.85	0.79	0.64	0.66	0.07	0.73	0.87	0.19	-0.07	-0.9	0.83	0.14	0.92		0.51	0.71	0.62	0.9	0.88	0.71	-0.35	0.89	0.82	0.65	0.87
Other Assets	0.77	0.53	0.71	0.78	0.77	0.37	0.73	0.6	0.55	-0.17	-0.23	0.64	0.21	0.71	0.51		0.75	0.78	0.6	0.46	0.75	-0.26	0.63	0.13	0.43	0.39
Long Term Debt	0.86	0.84	0.92	0.78	0.93	0.2	0.95	0.67	0.45	0.12	-0.62	0.52	-0.07	0.8	0.71	0.75		0.85	0.9	0.72	1.0	-0.56	0.9	0.41	0.76	0.63
Cash And Short Term Investments	1.0	0.7	0.93	0.93	0.94	0.46	0.92	0.75	0.62	-0.28	-0.52	0.69	0.32	0.82	0.62	0.78	0.85		0.81	0.7	0.85	-0.24	0.82	0.24	0.74	0.61
Common Stock Total Equity	0.82	0.95	0.95	0.7	0.89	0.05	0.94	0.87	0.23	0.07	-0.85	0.73	-0.01	0.93	0.9	0.6	0.9	0.81		0.95	0.9	-0.56	1.0	0.61	0.87	0.91
Common Stock Shares Outstanding	0.71	0.91	0.88	0.55	0.8	-0.12	0.84	0.94	0.0	0.09	-0.88	0.8	-0.04	0.91	0.88	0.46	0.72	0.7	0.95		0.72	-0.55	0.94	0.64	0.86	0.99
Long Term Debt Total	0.86	0.84	0.92	0.78	0.93	0.2	0.95	0.67	0.45	0.12	-0.62	0.52	-0.07	0.8	0.71	0.75	1.0	0.85	0.9	0.72		-0.56	0.9	0.41	0.76	0.63
Non Current Liabilities Total	-0.25	-0.56	-0.49	0.0	-0.55	0.68	-0.56	-0.41	0.44	-0.85	0.44	-0.18	0.82	-0.43	-0.35	-0.26	-0.56	-0.24	-0.56	-0.55	-0.56		-0.55	-0.34	-0.51	-0.53
Capital Surpluse	0.83	0.95	0.96	0.71	0.9	0.07	0.95	0.88	0.24	0.07	-0.83	0.74	-0.01	0.93	0.89	0.63	0.9	0.82	1.0	0.94	0.9	-0.55		0.59	0.87	0.9
Capital Lease Obligations	0.26	0.64	0.47	0.32	0.3	-0.17	0.38	0.66	-0.09	0.14	-0.9	0.61	-0.07	0.68	0.82	0.13	0.41	0.24	0.61	0.64	0.41	-0.34	0.59		0.41	0.65
Other Current Assets	0.75	0.93	0.88	0.55	0.82	0.05	0.83	0.76	0.17	0.08	-0.73	0.54	-0.05	0.73	0.65	0.43	0.76	0.74	0.87	0.86	0.76	-0.51	0.87	0.41		0.83
Other Stockholder Equity	0.63	0.88	0.81	0.46	0.72	-0.18	0.77	0.92	-0.09	0.09	-0.87	0.79	-0.04	0.87	0.87	0.39	0.63	0.61	0.91	0.99	0.63	-0.53	0.9	0.65	0.83

Click cells to compare fundamentals

NextCure Account Relationship Matchups

NextCure fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	356.2M	306.6M	242.4M	184.2M	129.4M	217.8M
Short Long Term Debt Total	587K	5.1M	3.5M	7.1M	6.6M	4.4M
Other Current Liab	5.0M	4.6M	4.7M	4.3M	3.9M	4.2M
Total Current Liabilities	15.0M	10.3M	6.6M	9.1M	6.9M	9.6M
Total Stockholder Equity	321.5M	293.7M	233.4M	167.5M	114.4M	166.4M
Other Liab	16.3M	792K	2.4M	899K	809.1K	768.6K
Net Tangible Assets	321.5M	293.7M	233.4M	167.5M	192.7M	173.2M
Property Plant And Equipment Net	12.1M	15.8M	14.0M	16.9M	13.4M	14.7M
Net Debt	(29.0M)	(29.3M)	(12.3M)	(19.5M)	(6.5M)	(6.8M)
Retained Earnings	(81.0M)	(117.6M)	(187.0M)	(261.8M)	(324.5M)	(308.3M)
Accounts Payable	1.9M	3.9M	1.9M	4.3M	2.3M	2.8M
Cash	34.1M	32.8M	12.3M	26.6M	13.1M	12.4M
Non Current Assets Total	16.2M	18.7M	14.6M	20.2M	16.7M	17.0M
Non Currrent Assets Other	750K	1.1M	577K	1.7M	1.9M	1.0M
Other Assets	436K	4.1M	2.9M	577K	3.3M	0.0
Cash And Short Term Investments	334.6M	283.4M	219.6M	159.9M	108.3M	196.3M
Common Stock Shares Outstanding	15.7M	27.5M	27.6M	27.7M	27.8M	23.0M
Short Term Investments	300.5M	250.7M	207.3M	133.3M	95.2M	155.1M
Liabilities And Stockholders Equity	356.2M	306.6M	242.4M	184.2M	129.4M	217.8M
Non Current Liabilities Total	19.6M	2.6M	2.4M	7.5M	8.1M	7.7M
Capital Surpluse	402.5M	410.6M	421.0M	430.8M	495.4M	305.3M
Capital Lease Obligations	127K	135K	0.0	7.1M	6.6M	6.9M
Other Current Assets	3.7M	2.8M	8.2M	4.1M	3.6M	3.6M
Other Stockholder Equity	46.4M	410.6M	421.0M	430.8M	439.1M	275.2M
Total Liab	34.7M	12.9M	9M	16.6M	15.0M	14.2M
Net Invested Capital	326.5M	297.2M	233.4M	167.5M	114.4M	168.0M
Property Plant And Equipment Gross	12.1M	15.8M	26.7M	33.5M	33.7M	22.5M
Total Current Assets	340.0M	288.0M	227.8M	164.0M	112.7M	200.8M
Accumulated Other Comprehensive Income	(38K)	779K	(663K)	(1.5M)	(222K)	(233.1K)
Net Working Capital	325.0M	277.7M	221.2M	154.9M	105.8M	191.1M
Short Term Debt	514K	1.8M	1.7M	518K	656K	1.0M
Property Plant Equipment	12.1M	15.8M	14.0M	11.9M	13.7M	13.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:

How To Invest In NextCure

Details

Is NextCure Stock a good investment?

Details

What is NextCure's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for NextCure Stock analysis

When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.

	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets

Is NextCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.28)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.29)

Return On Equity

(0.50)

The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NextCure Long Term Debt vs Current Deferred Revenue Analysis

Long Term Debt vs Current Deferred Revenue

Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Long Term Debt

Current Deferred Revenue

NextCure fundamental ratios Correlations

NextCure Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NextCure fundamental ratios Accounts

Also Currently Popular

Complementary Tools for NextCure Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Capital Surpluse	+ 1.0	Common Stock Total Equity
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Net Tangible Assets	+ 0.98	Other Current Liab

Cash	- 1.0	Net Debt
Capital Lease Obligations	- 0.9	Retained Earnings
Non Currrent Assets Other	- 0.9	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings
Other Stockholder Equity	- 0.87	Retained Earnings
Net Debt	- 0.86	Other Liab